Effect of <i>Cyclocarya paliurus</i> on Glucose Metabolism and Intestinal GLP-1 Secretion in Type 2 Diabetic Rats

ZOU Yaqian; CHEN Liang; MU Jia; WANG Yajing; CHEN Xumeng

doi:10.13386/j.issn1002-0306.2024040157

Volume 46 Issue 7

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Supplements

Science and Technology of Food Industry > 2025 > 46(7): 337-345. > DOI: 10.13386/j.issn1002-0306.2024040157

ZOU Yaqian, CHEN Liang, MU Jia, et al. Effect of Cyclocarya paliurus on Glucose Metabolism and Intestinal GLP-1 Secretion in Type 2 Diabetic Rats[J]. Science and Technology of Food Industry, 2025, 46(7): 337−345. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2024040157.

Citation:

PDF (4620 KB)

Effect of Cyclocarya paliurus on Glucose Metabolism and Intestinal GLP-1 Secretion in Type 2 Diabetic Rats

College of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China

More Information

Received Date: April 09, 2024
Available Online: February 06, 2025

Graphical Abstract

Abstract

Abstract

Objective: This study aimed to evaluate the hypoglycemic effect of Cyclocarya paliurus on type 2 diabetic rats and its impact on glucagon-like peptide-1 (GLP-1) secretion, and to preliminarily explore its mechanism. Methods: Type 2 diabetes was induced in rats using a high-fat, high-sugar diet combined with streptozotocin. Rats were then treated with low-dose (400 mg/kg) and high-dose (800 mg/kg) Cyclocarya paliurus, or metformin (150 mg/kg), via gavage for 8 weeks. Weekly assessments included body weight, food intake, and fasting glucose levels. After 8 weeks, an oral glucose tolerance test was conducted. Serum levels of glycated hemoglobin, fasting insulin, GLP-1, alanine aminotransferase, and aspartate aminotransferase were measured. Liver glycogen levels and glucokinase (GK) activity were assessed, and liver pathology was examined using HE staining. Real-time PCR analyzed mRNA expression of GCG, PC1/3 in colon tissues, and GK in liver tissues, while immunohistochemistry was used to detect GLP-1 protein expression in colon tissues. Results: Cyclocarya paliurus treatment (both low- and high-doses) effectively reduced food intake and stabilized body weight in diabetic rats, positively influencing their diabetes condition compared to the model group. Glycated hemoglobin and the insulin resistance index were significantly lower (P<0.01) in both low- and high-doses Cyclocarya paliurus-treated rats. Fasting insulin was significantly lower (P<0.01), while the insulin sensitivity index was significantly higher in the high-dose group than that in the model group (P<0.05). HE staining revealed improved liver pathology in Cyclocarya paliurus-treated groups. Immunohistochemistry and Real-time PCR results indicated increased GLP-1 expression and secretion in both circulating blood and colon tissues (P<0.05, P<0.01) and enhanced activity and mRNA expression of GK in liver (P<0.01). Additionally, hepatic glycogen levels were elevated (P<0.05, P<0.01). Conclusion: Cyclocarya paliurus could effectively stabilize blood glucose levels, improve insulin resistance, and regulate GLP-1 synthesis and secretion, which has a certain protective effect on the liver. These effects are mediated through the regulation of the liver-intestinal axis.
- Cyclocarya paliurus,
- type 2 diabetes,
- glucagon-like peptide-1,
- glucokinase,
- liver-intestinal axis

FullText(HTML)

References (40)

References

[1]	HARREITER J, RODEN M. Diabetes mellitus-Definition, classification, diagnosis, screening and prevention (Update 2019)[J]. Wien Klin Wochenschr,2019,131(Suppl 1):6−15.
[2]	BERBUDI A, RAHMADIKA N, TJAHJADI A I, et al. Type 2 diabetes and its impact on the immune system[J]. Current Diabetes Reviews,2020,16(5):442−449.
[3]	CHEW N W S, NG C H, TAN J H, et al. The global burden of metabolic disease:Data from 2000 to 2019[J]. Cell Metabolism,2023,35(3):414−428. doi: 10.1016/j.cmet.2023.02.003
[4]	陈靓, 田星, 邹雅倩, 等. 青钱柳水提物对果糖诱导的代谢综合征大鼠糖脂代谢的影响[J]. 食品与发酵工业,2023,49(18):232−241. [CHEN L, TIAN X, ZOU Y Q, et al. Effect and mechanism of aqueous extract of Cyclocarya paliurus on fructose-induced metabolic syndrome with glucolipid metabolism disorders in rats[J]. Food and Fermentation Industries,2023,49(18):232−241.] CHEN L, TIAN X, ZOU Y Q, et al. Effect and mechanism of aqueous extract of Cyclocarya paliurus on fructose-induced metabolic syndrome with glucolipid metabolism disorders in rats[J]. Food and Fermentation Industries, 2023, 49（18）: 232−241.
[5]	陈絮蒙, 王雅靖, 陈靓, 等. 青钱柳活性物质及其代谢调节作用的研究与应用进展[J]. 食品与发酵工业,2023,49(12):336−344. [CHEN X M, WANG Y J, CHEN L, et al. Research and application progress of active substances and their metabolic regulatory effects of Cyclocarya paliurus[J]. Food and Fermentation Industries,2023,49(12):336−344.] CHEN X M, WANG Y J, CHEN L, et al. Research and application progress of active substances and their metabolic regulatory effects of Cyclocarya paliurus[J]. Food and Fermentation Industries, 2023, 49（12）: 336−344.
[6]	PATEL S, SESHADRI S, DALAI S. Chapter seven-Gut microbiome and type 2 diabetes[J]. Progress in Molecular Biology and Translational Science,2022,191(1):175−185.
[7]	FANG X, MIAO R, WEI J, et al. Advances in multi-omics study of biomarkers of glycolipid metabolism disorder[J]. Comput Struct Biotechnol J,2022,25(20):5935−5951.
[8]	王雅靖, 陈靓, 邹雅倩, 等. 甜味植物调节胰高血糖素样肽-1防治糖尿病的研究进展[J]. 食品与发酵工业,2024,50(15):374−383. [WANG Y J, CHEN L, ZOU Y Q, et al. Progress of sweet-taste plants regulating glucagon-like peptide-1 against diabetes[J]. Food and Fermentation Industries,2024,50(15):374−383.] WANG Y J, CHEN L, ZOU Y Q, et al. Progress of sweet-taste plants regulating glucagon-like peptide-1 against diabetes[J]. Food and Fermentation Industries, 2024, 50（15）: 374−383.
[9]	ZHANG B, YU Z, ZHAO X, et al. Foodborne carbon dots aggravate high-fat-diet-induced glucose homeostasis imbalance by disrupting the gut-liver axis[J]. ACS Applied Materials & Interfaces,2024,16(10):12263−12276.
[10]	SMITH N K, HACKETT T A, GALLI A, et al. GLP-1:Molecular mechanisms and outcomes of a complex signaling system[J]. Neurochemistry International,2019,128(9):94−105.
[11]	TOULIS K A, NIRANTHARAKUMAR K, POURZITAKI C, et al. Glucokinase activators for type 2 diabetes:Challenges and future developments[J]. Drugs,2020,80(5):467−475. doi: 10.1007/s40265-020-01278-z
[12]	CHAO P C, LI Y, CHANG C H, et al. Investigation of insulin resistance in the popularly used four rat models of type-2 diabetes[J]. Biomed Pharmacother,2018,101(2):155−161.
[13]	肖瑶. 甜味受体介导代谢综合征形成及其风险标志物研究[D]. 武汉:武汉大学, 2020. [XIAO Y. The formation and biomarkers of metabolic syndrome mediated by sweet receptors[D]. Wuhan:Wuhan University, 2020.] XIAO Y. The formation and biomarkers of metabolic syndrome mediated by sweet receptors[D]. Wuhan: Wuhan University, 2020.
[14]	LIU F L, SHI K J, DONG J J, et al. Ganoderic acid attenuates high-fat-diet-induced liver injury in rats by regulating the lipid oxidation and liver inflammation[J]. Archives of Pharmacal Research,2020,43(7):744−754. doi: 10.1007/s12272-020-01256-9
[15]	LONGO S, RIZZA S, FEDERICI M. Microbiota-gut-brain axis:Relationships among the vagus nerve, gut microbiota, obesity, and diabetes[J]. Acta Diabetol,2023,60(8):1007−1017. doi: 10.1007/s00592-023-02088-x
[16]	WANG M, LI S, ZHANG X, et al. Association between hemoglobin glycation index and non-alcoholic fatty liver disease in the patients with type 2 diabetes mellitus[J]. Journal of Diabetes Investigation,2023,14(11):1303−1311. doi: 10.1111/jdi.14066
[17]	JAGANNATHAN R, NEVES J S, DORCELY B, et al. The oral glucose tolerance test:100 years later[J]. Diabetes, Metabolic Syndrome and Obesity,2020,19(13):3787−3805.
[18]	TONG Y, XU S, HUANG L, et al. Obesity and insulin resistance:Pathophysiology and treatment[J]. Drug Discovery Today,2022,27(3):822−830. doi: 10.1016/j.drudis.2021.11.001
[19]	SEINO Y, YAMAZAKI Y. Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity[J]. Journal of Diabetes Investigation,2022,13(7):1122−1128. doi: 10.1111/jdi.13816
[20]	TAN X, DIVINO V, AMAMOO J, et al. Real-world effectiveness of once-weekly glucagon-like peptide-1 receptor agonists (OW GLP-1RAs) in comparison with dipeptidyl peptidase-4 (DPP-4) inhibitors for glycemic control and weight outcomes in type 2 diabetes mellitus[J]. Clinical Drug Investigation,2024,44(4):271−284. doi: 10.1007/s40261-024-01354-2
[21]	周曦冉, 焦格娜, 曾己, 等. 萸精降糖方对2型糖尿病大鼠血糖血脂及血清氧化应激有关指标的影响[J]. 食品工业科技,2023,44(19):433−439. [ZHOU X, JIAO G N, ZENG J, et al. Effect of Yujing Jiangtang Recipe on blood glucose, lipid and serum oxidative stress related indexes in type 2 diabetes rats[J]. Science and Technology of Food Industry,2023,44(19):433−439.] ZHOU X, JIAO G N, ZENG J, et al. Effect of Yujing Jiangtang Recipe on blood glucose, lipid and serum oxidative stress related indexes in type 2 diabetes rats[J]. Science and Technology of Food Industry, 2023, 44（19）: 433−439.
[22]	黄盼玲, 肖颖梅, 李泊村, 等. 罗汉果皂苷改善糖尿病小鼠血糖的作用研究[J]. 食品研究与开发,2022,43(5):8−13. [HUANG P P, XIAO Y M, LI B C, et al. Mogroside improves glycemic control in diabetic mice[J]. Food Research and Development,2022,43(5):8−13.] doi: 10.12161/j.issn.1005-6521.2022.05.002 HUANG P P, XIAO Y M, LI B C, et al. Mogroside improves glycemic control in diabetic mice[J]. Food Research and Development, 2022, 43（5）: 8−13. doi: 10.12161/j.issn.1005-6521.2022.05.002
[23]	BAI L, GAO J, WEI F, et al. Therapeutic potential of ginsenosides as an adjuvant treatment for diabetes[J]. Frontiers in Pharmacology,2018,5(9):423−437.
[24]	FENG Z, FANG Z, CHEN C, et al. Anti-hyperglycemic effects of refined fractions from Cyclocarya paliurus leaves on streptozotocin-induced diabetic mice[J]. Molecules,2021,26(22):68−86.
[25]	王依婷, 赵梦鸽, 盛雪萍, 等. 青钱柳三萜酸对高糖所致的胰岛α细胞胰岛素抵抗的影响[J]. 中国药科大学学报,2018,49(2):215−221. [WANG Y T, ZHAO M G, SHENG X P, et al. Effect of triterpenic acid-enriched fraction from Cyclocarya paliurus on high glucose-induced pancreatic α-cells insulin resistance[J]. China Pharm Univ,2018,49(2):215−221.] doi: 10.11665/j.issn.1000-5048.20180212 WANG Y T, ZHAO M G, SHENG X P, et al. Effect of triterpenic acid-enriched fraction from Cyclocarya paliurus on high glucose-induced pancreatic α-cells insulin resistance[J]. China Pharm Univ, 2018, 49（2）: 215−221. doi: 10.11665/j.issn.1000-5048.20180212
[26]	CAO J J, ZHENG R D, CHANG X Y, et al. Cyclocarya paliurus triterpenoids suppress hepatic gluconeogenesis via AMPK-mediated cAMP/PKA/CREB pathway[J]. Phytomedicine,2022,102(7):154−175.
[27]	SUN E W, MARTIN A M, FONTGALLAND D D, et al. Evidence for glucagon secretion and function within the human gut[J]. Endocrinology,2021,162(4):1−12.
[28]	GRAU-BOVÉ C, GONZÁLEZ-QUILEN C, CANTINI G, et al. GLP-1 exerts paracrine activity in the intestinal lumen of human colon[J]. International Journal of Molecular Sciences,2022,23(7):3523−3536. doi: 10.3390/ijms23073523
[29]	MCLEAN B A, WONG C K, CAMPBELL J E, et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation[J]. Endocrine Reviews,2021,42(2):101−132. doi: 10.1210/endrev/bnaa032
[30]	MILOSEVIC I, VUJOVIC A, BARAC A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases:A review of the literature[J]. International Journal of Molecular Sciences,2019,20(2):395−411. doi: 10.3390/ijms20020395
[31]	KIM E R, PARK J S, KIM J H, et al. A GLP-1/GLP-2 receptor dual agonist to treat NASH:Targeting the gut-liver axis and microbiome[J]. Hepatology,2022,75(6):1523−1538. doi: 10.1002/hep.32235
[32]	李杰, 钱丽, 施晓卉, 等. 葡萄糖激酶激活剂研究进展可视化分析[J]. 中国药业,2023,32(20):50−55. [LI J, QIAN L, SHI X H, et al. Visual analysis of research progress on glucokinase activators[J]. China Pharmaceuticals,2023,32(20):50−55.] doi: 10.3969/j.issn.1006-4931.2023.12.013 LI J, QIAN L, SHI X H, et al. Visual analysis of research progress on glucokinase activators[J]. China Pharmaceuticals, 2023, 32（20）: 50−55. doi: 10.3969/j.issn.1006-4931.2023.12.013
[33]	REN Y, LI L, WAN L, et al. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists[J]. Journal of Enzyme Inhibition and Medicinal Chemistry,2022,37(1):606−615. doi: 10.1080/14756366.2021.2025362
[34]	GREWAL A S, LATHER V, CHARAYA N, et al. Recent developments in medicinal chemistry of allosteric activators of human glucokinase for type 2 diabetes mellitus therapeutics[J]. Current Pharmaceutical Design,2020,26(21):2510−2552. doi: 10.2174/1381612826666200414163148
[35]	CHOW E, WANG K, LIM C K P, et al. Dorzagliatin, a dual-acting glucokinase activator, increases insulin secretion and glucose sensitivity in glucokinase maturity-onset diabetes of the young and recent-onset type 2 diabetes[J]. Diabetes,2023,72(2):299−308. doi: 10.2337/db22-0708
[36]	YAO C X, QIAN Z, QIAO J H, et al. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition[J]. Acta Pharmaceutica Sinica B,2023,13(6):2383−2402. doi: 10.1016/j.apsb.2022.11.008
[37]	曹静静. 基于胰高血糖素/AMPK 途径研究青钱柳三萜酸干预糖异生的作用及机制[D]. 南京:南京中医药大学, 2021. [CAO J J. Study on the effect and mechanism of triterpenoid acid of Cyclocarya paliurus on gluconeogenesis based on glucagon/AMPK pathway[D]. Nanjing:Nanjing University of Traditional Chinese Medicine, 2021.] CAO J J. Study on the effect and mechanism of triterpenoid acid of Cyclocarya paliurus on gluconeogenesis based on glucagon/AMPK pathway[D]. Nanjing: Nanjing University of Traditional Chinese Medicine, 2021.
[38]	李楠. 青钱柳多糖对大鼠抗氧化及脂代谢相关基因表达的研究[D]. 南昌:江西农业大学, 2015. [LI N. Study on the effect of Cyclocarya paliurus polysaccharide on the expression of genes related to antioxidation and lipid metabolism in rats[D]. Nanchang:Jiangxi Agricultural University, 2015.] LI N. Study on the effect of Cyclocarya paliurus polysaccharide on the expression of genes related to antioxidation and lipid metabolism in rats[D]. Nanchang: Jiangxi Agricultural University, 2015.
[39]	EKBERG K, LANDAU B R, WAJNGOT A, et al. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting[J]. Diabetes,1999,48(2):292−298. doi: 10.2337/diabetes.48.2.292
[40]	FEBBRAIO M A, KARIN M. "Sweet death":Fructose as a metabolic toxin that targets the gut-liver axis[J]. Cell Metabolism,2021,33(12):2316−2328. doi: 10.1016/j.cmet.2021.09.004